UNSPSC 51171954: Pifarnine

This classification denotes an anti-ulcer agent with the molecular formula C27H40N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3W85193GZ4, chemically known as 4-farnesyl-1-(3,4-methylenedioxybenzyl)piperazine but generally known as pifarnine, which bears US NIH Compound Identifier 6436032. European Medicines Agency schedules Pifarnine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09827MIG.

UNSPSC 51171954 Pifarnine is a Commodity code covering pharmaceutical products, specifically immunoassay screening agents and drug-testing reagents used in specimen analysis for correctional and public-health applications. State and local governments procure pifarnine primarily through county correctional departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work involves supplying ready-to-use screening agents for five- and six-panel drug tests, confirmation reagents for LC/MS/MS and GC/MS instrumentation, and alternative testing methodologies including oral fluid and hair screening protocols. Issuing bodies include county community supervision and corrections departments, state health commissions, and multistate cooperative purchasing organizations; these entities typically aggregate annual testing volumes in the tens of thousands of tests and negotiate per-test pricing with fixed staffing and delivery terms.

Recent activity concentrates in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with proposals due July 23, 2026, specifying approximately 25,031 annual tests using immunoassay screening with LC/MS/MS or GC/MS confirmation, estimated contract value $600,000 over two years plus three optional one-year renewals, with vendor selection weighted 30 percent on understanding, 25 percent on qualifications, 15 percent on references, and 30 percent on cost. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring manufacturers to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling exploratory procurement activity ahead of formal solicitation.